Madrigal Pharma announces “positive” data from NASH trial

Human Internal Digestive Organ Liver Anatomy
magicmine/iStock via Getty Images

  • The shares of Madrigal Pharmaceuticals (MDGL +0.4%) pared early losses after the company announced what it called positive clinical data from an open-label portion of its ongoing Phase 3 MAESTRO-NAFLD-1 study for resmetirom in

Recommended For You

Comments (3)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.